EDP Sciences logo
Submit your paper
Search
Menu
Home All issues Volume 20 / No 2 (avril 2014) Med Buccale Chir Buccale, 20 2 (2014) 89-97 References
Open Access
Issue
Med Buccale Chir Buccale
Volume 20, Number 2, avril 2014
Page(s) 89 - 97
Section Revue de littérature / Literature review
DOI https://doi.org/10.1051/mbcb/2014005
Published online 13 May 2014
  1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370:1861-74. [CrossRef] [PubMed] [Google Scholar]
  2. bio-therapy.net - Recommandations de l’EULAR pour la prise en charge thérapeutique de la polyarthrite rhumatoïde [Internet]. http://www.bio-therapy.net/content/view/3577/229/ [Google Scholar]
  3. Kaur S, White S, Bartold PM. Periodontal disease and rheumatoid arthritis: a systematic review. J Dent Res 2013;92:399-408. [CrossRef] [PubMed] [Google Scholar]
  4. Monsarrat P, et al. Oral Health Status in Outpatients with Rheumatoid Arthritis: The OSARA Study. Oral Health Dent Manag 2014;13:113-9. [PubMed] [Google Scholar]
  5. Blaizot A, et al. Oral health-related quality of life among outpatients with rheumatoid arthritis. Int Dent J 2013;63: 45-53. [CrossRef] [Google Scholar]
  6. Société française de chirurgie orale [Internet]. [http://www. societechirorale.com/Recommandations/Recommandations.html [Google Scholar]
  7. Kawakami K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology 2010;49:341-7. [CrossRef] [PubMed] [Google Scholar]
  8. Agence nationale d’accréditation et d’évaluation en santé. Guide d’analyse de la littérature et gradation des recommandations [Internet]. 2000 http://www.has-sante.fr/portail/upload/docs/application/pdf/analiterat.pdf [Google Scholar]
  9. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-5. [PubMed] [Google Scholar]
  10. Ruyssen-Witrand A, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430-6. [PubMed] [Google Scholar]
  11. Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005;64:650-1. [CrossRef] [PubMed] [Google Scholar]
  12. Bongartz T, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1713-20. [CrossRef] [PubMed] [Google Scholar]
  13. den Broeder AA, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34:689-95. [PubMed] [Google Scholar]
  14. Wendling D, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 2005;64:1378-9. [CrossRef] [PubMed] [Google Scholar]
  15. Gilson M, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther 2010;12:R145. [CrossRef] [PubMed] [Google Scholar]
  16. Giles JT, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7. [CrossRef] [PubMed] [Google Scholar]
  17. Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y, Hobo K. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis 2011;14:31-6. [CrossRef] [PubMed] [Google Scholar]
  18. Ciantar M, Adlam DM. Treatment with infliximab: Implications in oral surgery? A case report. Br J Oral Maxillofac Surg 2007; 45:507-10. [CrossRef] [PubMed] [Google Scholar]
  19. Momohara S, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011;21:469-75. [CrossRef] [PubMed] [Google Scholar]
  20. Johnson BK, Goodman SM, Alexiades MM, Figgie MP, Demmer RT, Mandl LA. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol 2013;40:617-23. [CrossRef] [PubMed] [Google Scholar]
  21. Kubota A, Nakamura T, Miyazaki Y, Sekiguchi M, Suguro T. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 2012;22:844-8. [CrossRef] [PubMed] [Google Scholar]
  22. Suzuki M, Nishida K, Soen S, Oda H, Inoue H, Kaneko A, et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci 2011;16:778-84. [CrossRef] [PubMed] [Google Scholar]
  23. Hirano Y, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:495-500. [CrossRef] [PubMed] [Google Scholar]
  24. Bienvenue sur le Club Rhumatismes et Inflammations [Internet]. http://www.cri-net.com/recherche/fichespratiques/recommandations.asp [Google Scholar]
  25. Preidl RH, Ebker T, Raithel M, Wehrhan F, Neukam FW, Stockmann P. Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report. BMC Gastroenterol 2014;14:6. [CrossRef] [PubMed] [Google Scholar]
  26. Emori TG, et al. National nosocomial infections surveillance system [NNIS]: description of surveillance methods. Am J Infect Control 1991;19:19-35. [CrossRef] [PubMed] [Google Scholar]
  27. Blondeau F, Daniel NG. Extraction of impacted mandibular third molars: postoperative complications and their risk factors. J Can Dent Assoc 2007;73:325. [PubMed] [Google Scholar]
  28. Chadli M, et al. [Incidence of surgical wound infections a prospective study in the Rabat Mohamed-V military hospital, Morocco]. Med Mal Infect 2005;35:218-22. [CrossRef] [PubMed] [Google Scholar]
  29. Gaynes R, et al. Feeding back surveillance data to prevent hospital-acquired infections. Emerg Infect Dis 2001;7:295-8. [CrossRef] [PubMed] [Google Scholar]
  30. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003; 139:W-W63. [Google Scholar]
  31. Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010;49:2217-9. [CrossRef] [PubMed] [Google Scholar]
  32. Van Dartel SAA, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring [DREAM] registry. Ann Rheum Dis 2012; 72:895-900. [CrossRef] [PubMed] [Google Scholar]
  33. Atzeni F, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012;12:225-9. [CrossRef] [PubMed] [Google Scholar]
  34. Kremer J. The CORRONA database. Ann Rheum Dis 2005;64: iv37-iv41. [CrossRef] [PubMed] [Google Scholar]
  35. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology 2010;49:82-90. [CrossRef] [PubMed] [Google Scholar]
  36. Schneeweiss S, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64. [CrossRef] [PubMed] [Google Scholar]
  37. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2008;68:1136-45. [Google Scholar]
  38. Curtis JR, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor a antagonists. Arthritis Rheum 2007;56:1125-33. [CrossRef] [PubMed] [Google Scholar]
  39. Nam JL, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86. [CrossRef] [PubMed] [Google Scholar]
  40. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300. [CrossRef] [PubMed] [Google Scholar]
  41. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214-7. [CrossRef] [PubMed] [Google Scholar]
  42. Greenberg JD, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42. [CrossRef] [PubMed] [Google Scholar]
  43. Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery ? A systematic review of the evidence. Rheumatol Int 2011;32:5-13. [CrossRef] [Google Scholar]
  44. Iglesias E, O’Valle F, Salvatierra J, Aneiros-Fernández J, Cantero-Hinojosa J, Hernández-Cortés P. Effect of blockade of tumor necrosis factor-alpha with etanercept on surgical wound healing in SWISS-OF1 mice. J Rheumatol 2009;36:2144-8. [CrossRef] [PubMed] [Google Scholar]
  45. Klarenbeek NB, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-9. [CrossRef] [PubMed] [Google Scholar]
  46. Tanaka Y, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR [remission induction by Remicade in RA] study. Ann Rheum Dis 2010;69:1286-91. [CrossRef] [PubMed] [Google Scholar]
  47. Brocq O, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.